Wyeth Impax get court approval of Effexor patent suit settlement: related news

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today. Under the terms of the settlement, Wyeth has granted Impax a license that would permit Impax to launch its capsule formulation of Effexor XR on or after June 1, 2011, subject to earlier launch in limited circumstances, but in no event earlier than January 1, 2011. Impax will pay Wyeth a royalty on sales of this generic product. The parties also have agreed that Impax will utilize its neurology-focused sales force to promote a product to be na

Wyeth, Impax get court approval of Effexor patent suit settlement

SAN FRANCISCO (Thomson Financial) - Wyeth and Impax Laboratories Inc. said late Wednesday the companies' settlement of their patent infringement lawsuit related to Impax's generic version of Wyeth's Effexor XR has received court approval.

Wyeth, Impax get court approval of Effexor patent suit settlement

SAN FRANCISCO (Thomson Financial) - Wyeth and Impax Laboratories Inc. said late Wednesday the companies' settlement of their patent infringement lawsuit related to Impax's generic version of Wyeth's Effexor XR has received court approval.

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

MADISON, N.J., July 16 /PRNewswire-FirstCall/ -- Wyeth and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

MADISON, N.J., July 16 /PRNewswire-FirstCall/ -- Wyeth and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

MADISON, N.J., July 16 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

MADISON, N.J., July 16 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE - News) and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR® antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

MADISON, N.J., July 16, 2008 /PRNewswire-FirstCall via COMTEX/ -- WYE | Quote | Chart | News | PowerRating -- Wyeth (NYSE: WYE | Quote | Chart | News | PowerRating) and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of

Wyeth and Impax Announce Final Settlement of Effexor XR Patent Suit

PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) and Impax Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR(R) antidepressant have been approved by the United States District Court for the District of

Wyeth, Impax settle Effexor XR patent suit

Wyeth and Impax Laboratories Inc. announced that all conditions of a settlement of the US patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's Effexor XR antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective July 16, 2008.

Wyeth, Impax Settle Effexor XR Patent Suit

(RTTNews) - Wednesday, Wyeth (WYE: News, Chart, Quote ) and Impax Laboratories Inc. have announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to Impax's proposed generic capsule formulation of Wyeth's EFFEXOR XR antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective July 16.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Wyeth, Impax settle Effexor patent suit

Singapore, July 17, 2008: Pharmaceutical firms Wyeth and Impax Laboratories have announced that all conditions of a settlement of the US patent infringement litigation pertaining to Impax’s proposed generic capsule formulation of Wyeth’s Effexor XR antidepressant have been approved by the US district court for Delaware.

IMPAX ANNOUNCES FINAL SETTLEMENT OF GENERIC EFFEXOR XR PATENT SUIT

HAYWARD, Calif.--(BUSINESS WIRE)--July 16, 2008--IMPAX Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to IMPAX’s proposed generic capsule formulation of Wyeth’s EFFEXOR XR ® antidepressant have been approved by the United States District Court for the District of Delaware. The Court entered a consent judgment resulting in termination of the litigation effective today.

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,� said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

IMPAX ANNOUNCES FINAL SETTLEMENT OF GENERIC EFFEXOR XR PATENT SUIT

HAYWARD, Calif. - IMPAX Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to IMPAX’s proposed generic capsule formulation of Wyeth’s EFFEXOR XR

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

IMPAX ANNOUNCES FINAL SETTLEMENT OF GENERIC EFFEXOR XR PATENT SUIT

IMPAX Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to IMPAX

Wyeth settles patent dispute with Impax

Drug developer Wyeth said Wednesday a U.S. court approved a settlement with generic competitor Impax Laboratories, ending a patent lawsuit over an extended-release version of Wyeth's blockbuster antidepressant Effexor.

Wyeth settles patent dispute with Impax

NEW YORK (AP) -- Drug developer Wyeth said Wednesday a U.S. court approved a settlement with generic competitor Impax Laboratories, ending a patent lawsuit over an extended-release version of Wyeth's blockbuster antidepressant Effexor.

IMPAX ANNOUNCES FINAL SETTLEMENT OF GENERIC EFFEXOR XR PATENT SUIT

HAYWARD, Calif.-- (BUSINESS WIRE) -- IMPAX Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to IMPAX

Impax Announces Final Settlement of Generic Effexor Xr Patent Suit

HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories Inc. today announced that all conditions of a settlement of the U.S. patent infringement litigation pertaining to IMPAX

German court finds Qualcomm GSM patent suit against Nokia invalid

Today a German court ruled that Qualcomm's GSM patent suit against Nokia, filed in August of 2006, is invalid. This makes it the third such national court to so rule, the UK's High Court and the International Trade Commission in the USA having already ruled similarly. The same German court is set to rule on another Nokia/Qualcomm patent case in October.

Search took 0.45 seconds.